PTLA—Despite having Andexanet Alfa* collaborations with all participants in the FXa market, no one has apparently made a move to acquire the company and thereby obtain a competitive advnatge in the oral-anticoagulation market. This omission (IMO) speaks to the low value suitors are ascribing to PTLA’s Betrixaban program.
Market Data 
Markets 
AI
